Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...

Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't ...

Intellia Therapeutics (NASDAQ:NTLA) fell ~9% in the pre-market on Thursday after the biotech announced data from an ongoing ...

Intellia Therapeutics' Phase 2 data shows NTLA-2002, a CRISPR gene therapy, reduced hereditary angioedema attack rates by up to 81%, with complete responses.

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $17.5 to $20.0 for Intellia Therapeutics over the recent three months.

A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with ...

Preliminary results from a phase 1 trial run by Regeneron and CRISPR specialist Intellia Therapeutics – co-founded by Nobel Prize winner Jennifer Doudna – showed steep reductions in a ...

The promise of a one-and-done CRISPR in­fu­sion is be­gin­ning to look more re­al than ever. On Thurs­day, In­tel­lia ...

A single treatment with, a CRISPR-Cas9-based gene editing therapy ... Germany and France and an industry sponsor, Intellia, ...

For adults with hereditary angioedema, the in vivo gene-editing therapy NTLA-2002, which is based on clustered regul ...

The study, of Intellia’s treatment for hereditary angioedema, is the second Phase 3 trial the biotech has begun testing its “in vivo” gene editing medicines.

A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...